Alnylam’s CEO to Step Down at Year-End; Shares Slide
- Yvonne Greenstreet to join a handful of female biotech chiefs
- Maraganore oversaw company making RNAi a new drug class
This article is for subscribers only.
Alnylam Pharmaceuticals Inc. Chief Executive Officer John Maraganore, a legend in the biotech industry, will step down from his post at year-end to be succeeded by Chief Operating Officer Yvonne Greenstreet. The shares fell the most in three years.
Maraganore, 59, has led Alnylam since its founding in 2002. Under his leadership, the company turned a Nobel Prize-winning concept called RNA interference, or RNAi, into approved treatments for rare and deadly genetic conditions. Shares of Alnylam slid as much as 18%, their biggest intraday loss since April 2018, after gaining 47% this year through Wednesday.